Empowering Asthma Care: Bedfont® Scientific Limited Provides Vital Support for FeNO Testing

MAIDSTONE, U.K. - Amzeal -- Bedfont^® Scientific Ltd., world leaders in breath analysis with over 47 years of knowledge in designing and manufacturing medical breath analysis devices, welcomes the recent update to the National Institute for Health and Care Excellence (NICE) guidelines on asthma management.

Bedfont^® manufactures the NObreath^® Fractional exhaled Nitric Oxide (FeNO) device, which aids in diagnosing and managing asthma. Nitric oxide is a gas found in exhaled breath that indicates airway inflammation commonly found in eosinophilic asthma.

The previous guidelines for asthma management from NICE recommended FeNO testing alongside other objective tests, such as spirometry and peak flow. A FeNO reading of over 40 parts per billion (ppb) in adults and 35 ppb in children suggested a diagnosis of asthma if carried out with a positive spirometry or peak flow result.

More on Amzeal News

• $53 Million Company Valuation Investment with Majority Acquisition Option, Plus New Stock CUSIP Supporting Brand Transition of Fan Engagement Company
• Zeta Sky Helps Ontario Businesses Adapt to the Changing Cyber Threat Landscape
• $14M Deal with Famed David Lloyd for Sports, Entertainment & Gaming, AI Powered Fan Engagement Company; New Stock CUSIP; Creating Shareholder Value
• Disposable Vape Ban Spurs Hayati Innovation
• Prolific Hollywood "Unknown Actor" Leads 11 Day SoCal, Hands-On, Performer Employment Securing Residency that Shows Others How to Get More Work

So, what's new? NICE released the most recent asthma guidelines on Wednesday 27^th of November, which recommends a blood test to measure eosinophil levels, or a FeNO test to diagnose asthma in adults. A FeNO test is recommended as the first-line test for an asthma diagnosis in children. Confirmation of a positive asthma diagnosis is a FeNO level exceeding 50 ppb in adults and 35 ppb in children.

It is also proposed that FeNO tests should be offered at regular adult asthma reviews for monitoring, including before and after changing asthma medication. A FeNO test should also be undertaken if a patient presents with poorly controlled asthma.

Jason Smith, CEO at Bedfont^® comments "We welcome the updated NICE guidelines, which provide even greater clarity and emphasis on the role of FeNO testing in asthma care. These updates underscore the importance of FeNO testing as an essential tool in improving diagnostic accuracy and tailoring treatment plans to individual patient needs. At Bedfont^® we are proud to support healthcare professionals with our innovative NObreath^® (https://www.nobreathfeno.com/) FeNO testing device that aligns with the latest clinical guidance, ultimately helping to deliver better outcomes for people with asthma."

More on Amzeal News

• Dr. Harmon Completes Prestigious Zygomatic Implant Residency in Brazil
• Agreement to Deliver Thin-Film Solar Technology to Space Solar Array Provider, NASA Collaborative Agreement for Orbital Applications in Power Beaming
• Iterators LLC Honored with IST82 State Award for Accessibility in Massachusetts
• Josh & Heidi Share Upcoming "Spreading the Good BUZZ" Podcast Guests, Select Top Five Elopement Locations as Their Instagram Presence Grows Globally
• Opteamix Launches StackRewrite.AI to Transform Enterprise Legacy Modernization

In light of the changes to asthma care and management recommendations, Bedfont^® will host various educational resources, such as webinars and articles, to discuss these changes and what they mean for healthcare professionals carrying out FeNO tests.

For a more in-depth look at the guideline updates, read our latest article here (https://www.bedfont.com/new-nice-guidelines-for-asthma-feno-testing-and-the-nobreath-device-in-adult-and-paediatric-care/).

References

Asthma pathway (BTS, NICE, SIGN) [Internet]. National Institute for Health and Care Excellence. 2024. [Cited Wednesday 27th November 2024]. Available from: https://www.nice.org.uk/guidance/ng244